Chan Beals

Technik-/Wissenschafts-/F&E-Leiter bei Abide Therapeutics, Inc.

Health Technology

Finance

Aktive Positionen von Chan Beals

Unternehmen	Position	Beginn	Ende
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Technik-/Wissenschafts-/F&E-Leiter	06.01.2016	-

Massachusetts Institute of Technology

Undergraduate Degree

International

Vereinigte Staaten

Operativ

Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sektoral

Health Technology	2
Finance	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Private Unternehmen	1
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Health Technology

Private Unternehmen

Health Technology